Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

ISIN: SE0000872095 | Ticker: SOBI | LEI: 549300124Y3MQI87PT35
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Swedish Orphan Biovitrum

Company Description

At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care.

- Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care
- Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets
- A strong portfolio of on-market products, and an extensive portfolio of pre-market assets
- An international biopharmaceutical company covering the entire value chain
- We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation

Year founded

2010

Served area

Worldwide

Headcount

1,509

Headquarters

Tomtebodavägen 23A, 17165 Solna – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 48,283,000,000.00 48,661,000,000.00 52,496,000,000.00
Noncurrent Assets N/A 40,115,000,000.00 39,883,000,000.00 41,285,000,000.00
Property Plant And Equipment N/A 534,000,000.00 493,000,000.00 274,000,000.00
Deferred Tax Assets N/A 611,000,000.00 767,000,000.00 877,000,000.00
Current Assets N/A 8,168,000,000.00 8,778,000,000.00 11,210,000,000.00
Inventories N/A 3,053,000,000.00 3,424,000,000.00 3,332,000,000.00
Current Trade Receivables N/A 3,756,000,000.00 3,439,000,000.00 5,249,000,000.00
Other Current Receivables N/A 465,000,000.00 345,000,000.00 558,000,000.00
Cash and cash equivalents 737,000,000.00 404,000,000.00 1,045,000,000.00 1,361,000,000.00
Equity And Liabilities N/A 48,283,000,000.00 48,661,000,000.00 52,496,000,000.00
Equity N/A 20,206,000,000.00 23,203,000,000.00 26,525,000,000.00
Issued Capital N/A 167,000,000.00 169,000,000.00 N/A
Issued Capital Ordinary Shares N/A N/A 169,000,000.00 170,000,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A 2,679,000,000.00 2,638,000,000.00
Retained Earnings Excluding Profit Loss For Reporting Period N/A N/A 10,476,000,000.00 13,155,000,000.00
Other Reserves N/A -253,000,000.00 -66,000,000.00 351,000,000.00
Additional Paidin Capital N/A 9,816,000,000.00 9,945,000,000.00 10,211,000,000.00
Equity Attributable To Owners Of Parent N/A 20,206,000,000.00 23,203,000,000.00 26,525,000,000.00
Noncurrent Liabilities N/A 17,634,000,000.00 16,697,000,000.00 11,114,000,000.00
Noncurrent Provisions N/A 252,000,000.00 234,000,000.00 N/A
Deferred Tax Liabilities N/A 3,464,000,000.00 3,605,000,000.00 3,797,000,000.00
Other Noncurrent Financial Liabilities N/A 3,473,000,000.00 3,834,000,000.00 3,899,000,000.00
Longterm Borrowings N/A 10,137,000,000.00 8,777,000,000.00 2,971,000,000.00
Current Liabilities N/A 10,443,000,000.00 8,761,000,000.00 14,857,000,000.00
Current Provisions N/A N/A 267,000,000.00 499,000,000.00
Trade And Other Current Payables To Trade Suppliers N/A 569,000,000.00 558,000,000.00 1,252,000,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 4,700,000,000.00 5,253,000,000.00
Current Tax Liabilities Current N/A 518,000,000.00 40,000,000.00 23,000,000.00
Other Current Liabilities N/A 1,302,000,000.00 1,314,000,000.00 1,900,000,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 4,015,000,000.00 1,768,000,000.00 5,796,000,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 15,261,000,000.00 15,529,000,000.00 N/A
Revenue From Contracts With Customers N/A 15,529,000,000.00 18,790,000,000.00
Other Income 401,000,000.00 32,000,000.00 34,000,000.00
Profit Loss From Operating Activities 4,818,000,000.00 3,733,000,000.00 3,813,000,000.00
Finance Income 1,000,000.00 16,000,000.00 5,000,000.00
Finance Costs 602,000,000.00 454,000,000.00 497,000,000.00
Profit Loss Before Tax 4,217,000,000.00 3,295,000,000.00 3,321,000,000.00
Income Tax Expense Continuing Operations 972,000,000.00 616,000,000.00 683,000,000.00
Profit (loss) 3,245,000,000.00 2,679,000,000.00 2,638,000,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 3,245,000,000.00 2,679,000,000.00 2,638,000,000.00
Adjustments For Decrease Increase In Inventories N/A -1,325,000,000.00 -318,000,000.00 413,000,000.00
Other Adjustments For Noncash Items N/A 390,000,000.00 529,000,000.00 741,000,000.00
Interest Paid Classified As Operating Activities N/A 333,000,000.00 324,000,000.00 309,000,000.00
Interest Received Classified As Operating Activities N/A 1,000,000.00 0.00 5,000,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A N/A 1,124,000,000.00 673,000,000.00
Cash Flows From Used In Operating Activities N/A 4,926,000,000.00 5,470,000,000.00 4,665,000,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A 8,000,000.00 3,000,000.00 0.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 41,000,000.00 47,000,000.00 72,000,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 3,811,000,000.00 323,000,000.00 1,405,000,000.00
Cash Flows From Used In Investing Activities N/A -3,964,000,000.00 -367,000,000.00 -1,477,000,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 13,575,000,000.00 14,193,000,000.00 13,675,000,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 15,027,000,000.00 18,191,000,000.00 16,094,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 118,000,000.00 125,000,000.00 133,000,000.00
Cash Flows From Used In Financing Activities N/A -1,282,000,000.00 -4,474,000,000.00 -2,991,000,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A -320,000,000.00 629,000,000.00 197,000,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -13,000,000.00 12,000,000.00 119,000,000.00
Cash and cash equivalents 737,000,000.00 404,000,000.00 1,045,000,000.00 1,361,000,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
10.06.24 Christin Wesström Other Other SEK 0.00
03.06.24 Guido Oelkers Other Buy SEK 23,965,061.00
30.05.24 Guido Oelkers Other Sell SEK 32,090,302.00
15.05.24 Henrik Stenqvist Other Buy SEK 14,815,069.50
13.05.24 Henrik Stenqvist Other Sell SEK 20,766,484.20
13.05.24 Per Richard Torbjörn Hallberg Other Sell SEK 18,205,951.40
08.05.24 Daniel Rankin Other Sell SEK 13,836,769.39
08.05.24 Daniel Rankin Other Buy SEK 10,078,512.00
08.05.24 Daniel Rankin Other Sell SEK 2,586,093.35
13.02.24 Christin Wesström Other Buy SEK 3,835,982.20

Capital markets information

ISIN

SE0000872095

LEI

549300124Y3MQI87PT35

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.